Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cingulate Inc.CING · Entity 6983 | Director | February 25, 2022 | March 01, 2022 |
| Odyssey Health, Inc.ODYY · Entity 8618 | Director | May 19, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cingulate Inc.
Report date February 25, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2032-02-25 | Direct | 9,000 |
Reported balance
After 2022-02-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-25 · Grant · Acquired 9,000 · Balance 9,000 F1: The option vests on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the one-year anniversary of the date of grant.
Odyssey Health, Inc.
Report date May 19, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-05-18 | Direct | 1,250,000 |
Reported balance
After 2022-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-19 · Grant · Acquired 250,000 · Balance 1,250,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-05-19 | Direct | 1,500,000 |
Reported balance
After 2022-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-19 · Grant · Acquired 250,000 · Balance 1,500,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2022 Filed Jun 8, 2022 17:16 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.30 Strike: $0.30 | $75,000.00 |
DisclosureSEC source: 0001683168-22-004239 · ownership.xml · derivative · entry 2 Conroy Jeffrey X · CIK 0001794086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 250,000 shares Expires 2032-05-19 Read SEC document |
| May 19, 2022 Filed Jun 8, 2022 17:16 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.30 Strike: $0.30 | $75,000.00 |
DisclosureSEC source: 0001683168-22-004239 · ownership.xml · derivative · entry 1 Conroy Jeffrey X · CIK 0001794086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 250,000 shares Expires 2032-05-18 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:01 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-22-005776 · ownership.xml · derivative · entry 1 Conroy Jeffrey X · CIK 0001794086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-02-25 F1 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 23:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 8,983 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-21-031003 · ownership.xml · derivative · entry 1 Conroy Jeffrey X · CIK 0001794086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,983 Underlying: Common Stock · 8,983 shares Expires 2031-12-07 F1 · derivative.exercise_date: The option vests in four equal annual installments commencing on December 7, 2022. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:35 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantRestricted Stock Unit (Right to Buy) · Derivative | 500,000 | $0.45 Strike: $0.45 | $225,000.00 |
DisclosureSEC source: 0001683168-21-004318 · ownership.xml · derivative · entry 1 Conroy Jeffrey X · CIK 0001794086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_date: The vesting of the RSU (Units) is as follows: 500,000 RSU vest equally over 12 months, subject to the Grantee's continuous service through the applicable vesting date. If not forfeited, vesting of the Units will be accelerated and will vest in full immediately upon the closing of a Corporate Transaction, provided that Grantee provides Continuous Service to the Company through the date such Corporate Transaction is closed. Vested Units will be settled by delivering to Grantee a number of shares equal to the number of vested Units on the earlier of the date on which the Grantee's Continuous Service ends, or the closing of a Corporate Transaction. F2 · derivative.expiration_date: No expiration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.